Navigation Links
Potential concern about drugs in clinical trial
Date:12/19/2011

Drugs that enhance levels of small molecules derived naturally in the body from a major component of animal fats (small molecules known as epoxyeicosatrienoic acids [EETs]) are currently in clinical trials for the treatment of high blood pressure and diabetes. A team of researchers led by Dipak Panigrahy and Mark Kieran, at the Dana-Farber Cancer Institute, Boston; Sui Huang, at the Institute for Systems Biology, Seattle; and Darryl Zeldin, at the National Institute of Environmental Health Science, Research Triangle Park has now generated data in mice that raise concern about the use of these drugs in humans.

The key observation of the team was that EETs promote primary tumor growth and spread to distant sites (metastasis) in a variety of mouse models of cancer. As noted by the authors and, in an accompanying commentary, Raymond DuBois and Dingzhi Wang, at The University of Texas MD Anderson Cancer Center, Houston, the data generated suggest not only that raising levels of EETs in humans could have severe adverse effects but also that EET antagonists could provide a new approach to preventing and treating metastasis.


'/>"/>
Contact: Karen Honey
press_releases@the-jci.org
734-546-5242
Journal of Clinical Investigation
Source:Eurekalert

Page: 1

Related medicine news :

1. Moffitt Cancer Center researchers find potential target for treating metastatic cancer
2. Study participants at risk for Alzheimers want to know their potential fate
3. Mayo Clinic research improves diagnosis and potential treatment of neuromyelitis optica
4. NTU-led research probes potential link between cancer and a common chemical in consumer products
5. Dual-acting class of antimalarial compounds discovered by Novartis with potential to prevent and treat malaria
6. NIH-funded scientists identify potential malaria drug candidates
7. New smart material could help tap medical potential of tissue-penetrating light
8. Canadian researchers find potential new leukemia treatment with old antibiotic drug
9. Researchers reveal potential treatment for sickle cell disease
10. Neurologists identify potential biomarker of cognitive decline for earlier diagnosis of disease
11. Fighting fire with fire: Vampire bacteria has potential as living antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... ... ... “Congratulations! It's A Boy! God’s Gift: A Story of Love”: a children’s book ... A Boy! God’s Gift: A Story of Love” is the creation of published authors, ... by Christian Faith Publishing, Dale Anthony and Rachael Anthony’s new book is a perfect ...
(Date:8/18/2017)... , ... August 18, 2017 ... ... Quick International, LLC (“Quick”), a highly specialized asset-light logistics provider of complex ... into a definitive agreement to purchase Unitrans International Corporation, a division of ...
(Date:8/18/2017)... ... 18, 2017 , ... As an industry leader, Eppendorf is ... will present the line of epMotion automated liquid handling system. This automated liquid ... everyday pipetting tasks. , Ideal for scientists and lab technicians with no or ...
(Date:8/18/2017)... ... August 18, 2017 , ... Moore Insurance, a Houston ... east Texas, is launching a regional charity effort to provide publicity assistance and ... Pediatric Brain Tumor Foundation (PBTF) has raised nearly $30 million in donations that ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Golseth ... in the Dallas/Fort Worth area, is spearheading a regional charity campaign organized to provide ... , In early June of this year, Christina and her children returned from out ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017 AccuGenomics, Inc., a ... , today announced that the company has provided an ... of North Carolina at Chapel Hill and to Qura ... to characterize and quantify HIV reservoir and viral expression ... intervention. The HIV Cure Center is a joint initiative ...
(Date:8/8/2017)...  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company ... results for the second quarter ended June 30, 2017. ... 2017 and to date: ... the Company,s lead project, BL-8040: Announced ... as novel stem cell mobilization treatment for autologous bone-marrow ...
(Date:8/7/2017)... Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent specialty pharmacy, ...  All comparisons, unless otherwise noted, are to the quarter ended ... Second Quarter 2017 Highlights include: Revenue ... 3.5% Total prescriptions dispensed of 220,000, compared ... 7.6% Gross profit per prescription dispensed ...
Breaking Medicine Technology: